Engineered immune cells target Hard-to-Treat ovarian cancer
NCT ID NCT03017131
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new approach for people with ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard treatments. Patients receive their own T cells, which are genetically modified to recognize and attack cancer cells, along with a drug called decitabine that may make cancer cells more visible to the immune system. The main goal is to check safety and side effects in about 9 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New targeted therapy shows promise for Tough-to-Treat ovarian cancer
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
- Keytruda takes on genetic weak spots in advanced tumors